WO2015066668A8 - Methods of removing alpha-galactose - Google Patents

Methods of removing alpha-galactose Download PDF

Info

Publication number
WO2015066668A8
WO2015066668A8 PCT/US2014/063796 US2014063796W WO2015066668A8 WO 2015066668 A8 WO2015066668 A8 WO 2015066668A8 US 2014063796 W US2014063796 W US 2014063796W WO 2015066668 A8 WO2015066668 A8 WO 2015066668A8
Authority
WO
WIPO (PCT)
Prior art keywords
galactose
methods
removing alpha
alpha
tissue products
Prior art date
Application number
PCT/US2014/063796
Other languages
French (fr)
Other versions
WO2015066668A1 (en
Inventor
Hui Xu
Li Ting HUANG
Hua Wan
Rick Owens
Nathaniel Bachrach
Original Assignee
Lifecell Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112016009178-7A priority Critical patent/BR112016009178B1/en
Priority to DK14802997.8T priority patent/DK3065790T3/en
Priority to EP14802997.8A priority patent/EP3065790B1/en
Priority to ES14802997T priority patent/ES2846758T3/en
Priority to CN201480058533.3A priority patent/CN105682697B/en
Priority to AU2014341866A priority patent/AU2014341866B2/en
Application filed by Lifecell Corporation filed Critical Lifecell Corporation
Priority to CA2925332A priority patent/CA2925332C/en
Priority to JP2016527404A priority patent/JP6524597B2/en
Priority to EP20203388.2A priority patent/EP3799893A1/en
Publication of WO2015066668A1 publication Critical patent/WO2015066668A1/en
Publication of WO2015066668A8 publication Critical patent/WO2015066668A8/en
Priority to AU2018236910A priority patent/AU2018236910A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/362—Skin, e.g. dermal papillae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3695—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking

Abstract

Tissue products lacking a desired percentage of immunogenic epitopes, such as galactose alpha-1,3 galactose epitopes, are provided. Methods of making and using the tissue products are also provided.
PCT/US2014/063796 2013-11-04 2014-11-04 Methods of removing alpha-galactose WO2015066668A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DK14802997.8T DK3065790T3 (en) 2013-11-04 2014-11-04 ALPHA-GALACTOSE REMOVAL PROCEDURES
EP14802997.8A EP3065790B1 (en) 2013-11-04 2014-11-04 Methods of removing alpha-galactose
ES14802997T ES2846758T3 (en) 2013-11-04 2014-11-04 Methods to remove alpha-galactose
CN201480058533.3A CN105682697B (en) 2013-11-04 2014-11-04 Method for removing alpha-galactose
AU2014341866A AU2014341866B2 (en) 2013-11-04 2014-11-04 Methods of removing alpha-galactose
BR112016009178-7A BR112016009178B1 (en) 2013-11-04 2014-11-04 METHOD OF PREPARING A FABRIC PRODUCT AND USE OF A FABRIC PRODUCT
CA2925332A CA2925332C (en) 2013-11-04 2014-11-04 Methods of removing alpha-galactose
JP2016527404A JP6524597B2 (en) 2013-11-04 2014-11-04 Method of removing alpha-galactose
EP20203388.2A EP3799893A1 (en) 2013-11-04 2014-11-04 Methods of removing alpha-galactose
AU2018236910A AU2018236910A1 (en) 2013-11-04 2018-10-02 Methods of removing alpha-galactose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899647P 2013-11-04 2013-11-04
US61/899,647 2013-11-04

Publications (2)

Publication Number Publication Date
WO2015066668A1 WO2015066668A1 (en) 2015-05-07
WO2015066668A8 true WO2015066668A8 (en) 2015-07-02

Family

ID=51982769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/063796 WO2015066668A1 (en) 2013-11-04 2014-11-04 Methods of removing alpha-galactose

Country Status (10)

Country Link
US (2) US10307510B2 (en)
EP (2) EP3065790B1 (en)
JP (1) JP6524597B2 (en)
CN (1) CN105682697B (en)
AU (2) AU2014341866B2 (en)
BR (1) BR112016009178B1 (en)
CA (1) CA2925332C (en)
DK (1) DK3065790T3 (en)
ES (1) ES2846758T3 (en)
WO (1) WO2015066668A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106860861B (en) * 2017-03-03 2020-11-03 北京博辉瑞进生物科技有限公司 Immunity enhancing composition, preparation method and application thereof
JP6772390B2 (en) 2017-03-06 2020-10-21 ティーイーアイ バイオサイエンシズ，インコーポレイテッド Perforated tissue graft
SG11202011723XA (en) * 2018-07-02 2020-12-30 Gebauer Klopotek Patent Verwaltungs Ug Stabilization of collagen scaffolds
WO2021034928A1 (en) * 2019-08-20 2021-02-25 Lifecell Corporation Method of manufacturing particulate tissue products
CN111632196A (en) * 2020-06-01 2020-09-08 内蒙古自治区中医药研究所 Preparation method of acellular matrix for removing alpha-galactosyl antigen
CN114276974A (en) * 2021-12-24 2022-04-05 上海理工大学 Interstitial material for encapsulating cells and preparation method and application thereof
CN114377206B (en) * 2021-12-24 2022-09-30 杭州华迈医疗科技有限公司 Preparation method of acellular matrix biological material

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5230097A (en) 1975-09-02 1977-03-07 Kaneyasu Miyata Method of mounting different substitute blood vessel
US4801299A (en) 1983-06-10 1989-01-31 University Patents, Inc. Body implants of extracellular matrix and means and methods of making and using such implants
US5116615A (en) 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
MY107433A (en) 1989-10-12 1995-12-30 Imutran Ltd Modiefied biological material.
US5846715A (en) 1990-05-11 1998-12-08 The Austin Research Institute CD46 variants
AU650045B2 (en) 1990-09-12 1994-06-09 Lifecell Corporation Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions
US8067149B2 (en) 1990-09-12 2011-11-29 Lifecell Corporation Acellular dermal matrix and method of use thereof for grafting
US5336616A (en) 1990-09-12 1994-08-09 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
US5374539A (en) 1991-06-17 1994-12-20 Nimni; Marcel E. Process for purifying collagen and generating bioprosthesis
EP0689597A4 (en) 1993-03-16 1998-10-21 Austin Research Inst USE OF PORCINE GAL -g(a)(1,3) GALACTOSYL TRANSFERASE IN XENOGRAFT THERAPIES
US6331658B1 (en) 1993-04-20 2001-12-18 Integris Baptist Medical Center, Inc. Genetically engineered mammals for use as organ donors
US5460962A (en) 1994-01-04 1995-10-24 Organogenesis Inc. Peracetic acid sterilization of collagen or collagenous tissue
WO1995020661A1 (en) 1994-01-27 1995-08-03 Bresatec Ltd. Materials and methods for management of hyperacute rejection in human xenotransplantation
US5849991A (en) 1994-01-27 1998-12-15 Bresatch Limited Mice homozygous for an inactivated α 1,3-galactosyl transferase gene
DE69535752D1 (en) 1994-04-13 2008-06-26 Biotransplant Inc ALPHA (1,3) GALACTOSYL TRANSFERASE NEGATIVE PIG
CA2192660A1 (en) 1994-06-15 1995-12-21 Mauro S. Sandrin Methods for reducing hyperacute rejection of xenografts
US5547681A (en) 1994-07-14 1996-08-20 Union Carbide Chemicals & Plastics Technology Corporation Dermal patch
AUPM772494A0 (en) 1994-08-30 1994-09-22 Austin Research Institute, The Improvements in production of proteins in host cells
EP0821573A4 (en) 1995-04-19 2000-08-09 St Jude Medical Matrix substrate for a viable body tissue-derived prosthesis and method for making the same
US5782915A (en) 1995-09-15 1998-07-21 Stone; Kevin R. Articular cartilage heterografts
US6166288A (en) 1995-09-27 2000-12-26 Nextran Inc. Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor
EP0874900B1 (en) 1996-08-02 2007-10-03 The Austin Research Institute Improved nucleic acids encoding a chimeric glycosyltransferase
US6455037B1 (en) 1996-11-01 2002-09-24 Mount Sinai School Of Medicine Of The City University Of New York Cells expressing an αgala nucleic acid and methods of xenotransplantation
JP4676580B2 (en) 1996-11-05 2011-04-27 パーデュー・リサーチ・ファウンデーション Myocardial graft composition
AU732726B2 (en) 1996-12-10 2001-04-26 Purdue Research Foundation Biomaterial derived from vertebrate liver tissue
CA2267310C (en) 1996-12-10 2012-09-18 Purdue Research Foundation Stomach submucosa derived tissue graft
ES2513043T3 (en) 1997-03-26 2014-10-24 Imperial Innovations Limited Cell membrane anchored anticoagulant fusion protein
WO1998046165A1 (en) 1997-04-11 1998-10-22 Cryolife, Inc. Tissue decellularization
EP0989867B1 (en) 1997-06-27 2002-04-24 BADER, Augustinus Biosynthetic transplant and method for the production thereof
US6613278B1 (en) 1998-11-13 2003-09-02 Regeneration Technologies, Inc. Tissue pooling process
US6482584B1 (en) 1998-11-13 2002-11-19 Regeneration Technologies, Inc. Cyclic implant perfusion cleaning and passivation process
US6652818B1 (en) 1998-11-13 2003-11-25 Regeneration Technologies, Inc. Implant sterilization apparatus
US6371992B1 (en) 1997-12-19 2002-04-16 The Regents Of The University Of California Acellular matrix grafts: preparation and use
CA2349562A1 (en) 1998-03-06 1999-09-10 Crosscart, Inc. Soft tissue xenografts
US6383732B1 (en) 1999-02-11 2002-05-07 Crosscart, Inc. Method of preparing xenograft heart valves
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
KR101085210B1 (en) 1998-03-20 2011-11-21 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 Control of gene expression
GB9809280D0 (en) 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
US6432710B1 (en) 1998-05-22 2002-08-13 Isolagen Technologies, Inc. Compositions for regenerating tissue that has deteriorated, and methods for using such compositions
AU758703C (en) 1998-05-26 2004-06-03 Lifecell Corporation Cryopreservation of human red blood cells
EP1087756B1 (en) 1998-06-19 2009-08-05 Lifecell Corporation Particulate acellular tissue matrix
US6933326B1 (en) 1998-06-19 2005-08-23 Lifecell Coporation Particulate acellular tissue matrix
US6734018B2 (en) 1999-06-07 2004-05-11 Lifenet Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced
US8563232B2 (en) 2000-09-12 2013-10-22 Lifenet Health Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced
US6743574B1 (en) 2000-09-12 2004-06-01 Lifenet Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced
GB2345638A (en) 1998-09-11 2000-07-19 Tissue Science Lab Limited Injectable collagen compositions
US20020110609A1 (en) 1998-12-28 2002-08-15 David Hung Increasing retrievable fluid from a breast duct
WO2000042174A1 (en) 1999-01-13 2000-07-20 Ppl Therapeutics (Scotland) Limited Double nuclear transfer method and results thereof
US6267786B1 (en) * 1999-02-11 2001-07-31 Crosscart, Inc. Proteoglycan-reduced soft tissue xenografts
US20030068815A1 (en) 1999-02-11 2003-04-10 Stone Kevin R. Sterilized xenograft tissue
US20020012660A1 (en) 1999-03-04 2002-01-31 Alan Colman Method of preparing a somatic cells for nuclear transfer
CN1266716A (en) 1999-03-12 2000-09-20 中国人民解放军第四军医大学第一附属医院 Cross-linking type acellular pork skin
US6381026B1 (en) 1999-03-15 2002-04-30 Lifecell Corp. Method of measuring the contour of a biological surface
US8232320B2 (en) 1999-04-28 2012-07-31 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
WO2001030992A2 (en) 1999-10-22 2001-05-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education α1-3 GALACTOSYLTRANSFERASE GENE AND PROMOTER
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US6866686B2 (en) 2000-01-28 2005-03-15 Cryolife, Inc. Tissue graft
WO2001078798A1 (en) 2000-02-10 2001-10-25 Regeneration Technologies, Inc. Assembled implant
US20070009586A1 (en) 2000-02-29 2007-01-11 Cohen Kelman I Wound dressings containing complexes of transition metals and alginate for elastase sequestering
AU2001261650A1 (en) 2000-05-15 2001-11-26 Geron Corporation Ovine tissue for xenotransplantation
CA2419817C (en) 2000-08-16 2014-11-18 Duke University Decellularized tissue engineered constructs and tissues
WO2002017936A1 (en) 2000-08-28 2002-03-07 Collagenesis, Inc. Methods for processing animal tissues
US20020077697A1 (en) 2000-12-15 2002-06-20 Ranieri John Paul Processed ratite carotid arteries as xenogeneic small bore vascular grafts
WO2002074948A2 (en) 2001-03-21 2002-09-26 Geron Corporation Animal tissue with carbohydrate antigens compatible for human transplantation
US6933103B1 (en) 2001-03-21 2005-08-23 Brennen Medical, Inc. Biocompatible tissue for therapeutic use and method of making same
US7126039B2 (en) 2001-03-21 2006-10-24 Geron Corporation Animal tissue with carbohydrate antigens compatible for human transplantation
US7166278B2 (en) 2001-04-30 2007-01-23 Rbc Biotechnology, Inc. Modified organs and cells for xenotransplantation
US20040234507A1 (en) 2001-05-07 2004-11-25 Stone Kevin R Submucosal xenografts
WO2002092791A1 (en) 2001-05-14 2002-11-21 Stell Tissues or organs for use in xenotransplantation
GB2375771A (en) 2001-05-24 2002-11-27 Univ Leeds Decellularisation of tissue implant material
US7087089B2 (en) 2001-06-28 2006-08-08 Cook Biotech Incorporated Graft prosthesis devices containing renal capsule collagen
TWI284665B (en) 2001-08-17 2007-08-01 Univ Nat Cheng Kung Fabrication method of the porous collagen matrix
WO2003027298A1 (en) 2001-09-27 2003-04-03 Timothy Albert Holton Stem-loop vector system
JP4451658B2 (en) 2001-10-18 2010-04-14 ライフセル コーポレーション Tissue and organ remodeling
AU2002364596A1 (en) 2001-12-21 2003-07-15 Immerge Biotherapeutics, Inc. Knockout swine and methods for making the same
CN1582332A (en) 2001-12-29 2005-02-16 Seoul大学校产学协力财团 GFP-transfected clon pig, GT knoc-out clon pig and methos for production thereof
CN1774255A (en) 2002-02-22 2006-05-17 英特拉舍尔资源有限责任公司 Sterile immunogenic non-tumorigenic tumor cell compositions and methods
AU2003221809A1 (en) 2002-04-05 2003-10-27 Novozymes North America, Inc. Improvement of strength and abrasion resistance of durable press finished cellulosic materials
DE60333277D1 (en) 2002-05-02 2010-08-19 Purdue Research Foundation TRANSPLANT CONSTRUCTS WITH IMPROVED VASCULARIZATION
AUPS242702A0 (en) 2002-05-21 2002-06-13 Colltech Australia Limited Improved method for the extraction and purification of collagen
US6835385B2 (en) 2002-06-14 2004-12-28 Carol J. Buck Compositions and methods for softening, thinning and removing hyperkeratotic tissue
US20050256588A1 (en) 2002-06-28 2005-11-17 Cardio, Inc. Decellularized tissue
CA2507486A1 (en) 2002-08-14 2004-02-26 Immerge Biotherapeutics, Inc. .alpha.(1,3)-galactosyltransferase null cells, methods of selecting and .alpha.(1,3)-galactosyltransferase null swine produced therefrom
CA2899360A1 (en) 2002-08-21 2004-04-08 Revivicor, Inc. Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
US20040037735A1 (en) 2002-08-23 2004-02-26 Depaula Carl Alexander Allograft tissue purification process for cleaning bone
AU2003211379A1 (en) 2002-08-28 2004-03-19 Kinki University Process for producing collagen treated with cysteine protease and collagen treated with cysteine protease
JP3658385B2 (en) 2002-09-20 2005-06-08 佳宏 高見 Method for decellularization of skin, decellularized dermal matrix by the method, method for producing the same, and complex cultured skin using the matrix
US7402319B2 (en) 2002-09-27 2008-07-22 Board Of Regents, The University Of Texas System Cell-free tissue replacement for tissue engineering
AU2003302387A1 (en) 2002-11-26 2004-06-18 Crosscart, Inc. Substantially non-immunogenic injectable collagen
US20040187877A1 (en) * 2002-12-04 2004-09-30 Badylak Stephen F. Method for repair of liver tissue
US20040191226A1 (en) 2002-12-04 2004-09-30 Badylak Stephen F. Method for repair of body wall
US7118901B2 (en) 2002-12-18 2006-10-10 Roche Diagnostics Operations, Inc. Recombinant bovine pancreatic desoxyribonuclease I with high specific activity
US20040176855A1 (en) 2003-03-07 2004-09-09 Acell, Inc. Decellularized liver for repair of tissue and treatment of organ deficiency
US20040175366A1 (en) 2003-03-07 2004-09-09 Acell, Inc. Scaffold for cell growth and differentiation
US7067298B2 (en) 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
WO2004108904A2 (en) 2003-06-06 2004-12-16 University Of Pittsburgh Porcine cmp-n-acetylneuraminic acid hydroxylase gene
US20050013870A1 (en) 2003-07-17 2005-01-20 Toby Freyman Decellularized extracellular matrix of conditioned body tissues and uses thereof
CA2533259C (en) 2003-07-21 2014-01-28 Lifecell Corporation Acellular tissue matrices made from galactose .alpha.-1,3-galactose-deficient tissue
AU2004290006A1 (en) 2003-11-05 2005-05-26 University Of Pittsburgh Porcine isogloboside 3 synthase protein, cDNA, genomic organization, and regulatory region
WO2005081714A2 (en) 2003-11-21 2005-09-09 Revivicor, Inc. Use of interfering rna in the production of transgenic animals
US20050186286A1 (en) 2004-02-25 2005-08-25 Yoshihiro Takami Skin decellularization method, acellular dermal matrix and production method therefore employing said decellularization method, and composite cultured skin employing said matrix
CA2857051A1 (en) 2004-03-17 2005-09-29 David Ayares Tissue products derived from animals lacking any expression of functional alpha 1,3 galactosyltransferase
CA2565986A1 (en) 2004-05-07 2005-11-24 University Of Pittsburgh Of The Commnonwealth System Of Higher Education Porcine forssman synthetase protein, cdna, genomic organization, and regulatory region
US20050266390A1 (en) 2004-06-01 2005-12-01 Yuichiro Ueda Processes for removing cells and cell debris from tissue and tissue constructs used in transplantation and tissue reconstruction
US20060073592A1 (en) 2004-10-06 2006-04-06 Wendell Sun Methods of storing tissue matrices
WO2006074373A2 (en) 2005-01-06 2006-07-13 Crosscart, Inc. Immunochemically modified and sterilized xenografts and allografts
WO2006095342A2 (en) * 2005-03-07 2006-09-14 Technion Research & Development Foundation Ltd. Natural tissue-derived decellularized matrix and methods of generating and using same
US7723108B2 (en) 2005-03-16 2010-05-25 Musculoskeletal Transplant Foundation Soft tissue processing
US20100112543A1 (en) 2005-03-16 2010-05-06 Manh-Dan Ngo Processing soft tissue, methods and compositions related thereto
CN101272815B (en) 2005-08-26 2012-09-26 明尼苏达大学董事会 Decellularization and recellularization of organs and tissues
JP5002805B2 (en) 2005-10-14 2012-08-15 財団法人ヒューマンサイエンス振興財団 Production method of biological scaffold
GB0606231D0 (en) 2006-03-29 2006-05-10 Univ Leeds Improvements relating to decellurisation of tissue matrices for bladder implantation
US20070248575A1 (en) 2006-04-19 2007-10-25 Jerome Connor Bone graft composition
JP5050197B2 (en) 2006-07-31 2012-10-17 財団法人ヒューマンサイエンス振興財団 Production method of biological scaffold
CN104623643A (en) 2006-10-06 2015-05-20 人类起源公司 Natural (telopeptide) placental collagen compositions
JP5732197B2 (en) 2006-11-16 2015-06-10 ユニヴァーシティ・オヴ・リーズ Tissue preparation for meniscal implantation
AU2008237732B2 (en) 2007-04-16 2014-05-22 Covidien Ag Methods and compositions for tissue regeneration
WO2008125851A2 (en) 2007-04-16 2008-10-23 Tissue Science Laboratories Plc Vascular implant
KR20100005105A (en) 2007-05-06 2010-01-13 민병현 Therapeutic composite for cartilage disorder using extracellular matrix (ecm) scaffold
US20080306610A1 (en) 2007-06-07 2008-12-11 Zimmer Orthobiologics, Inc. Tissue processing for nonimmunogenic implants
US20100296969A1 (en) 2007-06-12 2010-11-25 Musculoskeletal Transplant Foundation Process for sterilizing acellular soft tissue under vacuum
US20100291532A1 (en) 2007-06-12 2010-11-18 Musculoskeletal Transplant Foundation Process for sterilizing acellular soft tissue with irradiation
AU2008275072B2 (en) 2007-07-10 2013-03-14 Lifecell Corporation Acellular tissue matrix compositions for tissue repair
CZ301086B6 (en) 2007-10-17 2009-11-04 Bio-Skin, A. S. Sterile autogenous, allogenic or xenogenic implant and process for preparing thereof
TWI353845B (en) 2008-03-19 2011-12-11 Food Industry Res & Dev Inst Process for preparing peptide products for promoti
GB0807868D0 (en) 2008-04-30 2008-06-04 Knight David P Cartilage repair material and a method for the preparation thereof
ES2755178T3 (en) 2008-06-06 2020-04-21 Lifecell Corp Tissue Matrix Elastase Treatment
ES2553762T3 (en) 2009-02-18 2015-12-11 Cormatrix Cardiovascular, Inc. Compositions and methods to prevent cardiac arrhythmia
US9155323B2 (en) 2009-05-15 2015-10-13 Siebte Pmi Verwaltungs Gmbh Aqueous process for preparing protein isolate and hydrolyzed protein from an oilseed
US8198408B2 (en) 2009-07-27 2012-06-12 National Cheng Kung University Method for preparing porous collagen matrices
WO2011019361A1 (en) 2009-08-11 2011-02-17 Tissue Banks International Acellular dermal allografts and method of preparation
US9566369B2 (en) 2010-02-26 2017-02-14 Decell Technologies Inc. Methods for tissue decellularization
GB2482166A (en) 2010-07-22 2012-01-25 Tissue Science Lablratories Ltd Manufacture of collagenous material from use in therapy from collagen particles
US9238793B2 (en) 2011-04-28 2016-01-19 Lifecell Corporation Method for enzymatic treatment of tissue products
US10207025B2 (en) 2011-04-28 2019-02-19 Lifecell Corporation Method for enzymatic treatment of tissue products
CN105854083A (en) * 2011-04-28 2016-08-17 生命细胞公司 Method for enzymatic treatment of tissue products
US20130122583A1 (en) 2011-11-10 2013-05-16 Celxcel Pty Ltd Sterilization process
EP3488878A1 (en) * 2012-03-08 2019-05-29 LifeCell Corporation Enzyme-activated collagen and tissue matrices

Also Published As

Publication number Publication date
AU2014341866A1 (en) 2016-04-07
EP3799893A1 (en) 2021-04-07
US20150126453A1 (en) 2015-05-07
BR112016009178B1 (en) 2020-12-15
WO2015066668A1 (en) 2015-05-07
JP6524597B2 (en) 2019-06-05
US10307510B2 (en) 2019-06-04
ES2846758T3 (en) 2021-07-29
DK3065790T3 (en) 2021-02-01
CA2925332A1 (en) 2015-05-07
US20190231931A1 (en) 2019-08-01
CA2925332C (en) 2022-07-12
AU2018236910A1 (en) 2018-10-18
EP3065790A1 (en) 2016-09-14
CN105682697B (en) 2022-10-14
EP3065790B1 (en) 2020-10-28
AU2014341866B2 (en) 2018-07-05
JP2016536315A (en) 2016-11-24
CN105682697A (en) 2016-06-15
BR112016009178A8 (en) 2020-03-24

Similar Documents

Publication Publication Date Title
EP3215603A4 (en) Engineered three-dimensional skin tissues, arrays thereof, and methods of making the same
WO2015066668A8 (en) Methods of removing alpha-galactose
EP3356595A4 (en) Processes for producing nanocellulose, and nanocellulose compositions produced therefrom
EP3684434A4 (en) Tissue construct, methods of producing and using the same
EP3733715A4 (en) Triabody, preparation method and use thereof
WO2013096741A3 (en) Organoids comprising decellularized and repopulated placental vascular scaffold
EP3409282A4 (en) Solid preparation, method for producing solid preparation, and method for generating hydrogen
EP3427822A4 (en) Catalyst for preparing 2,5-furancarboxylic acid and method for preparing 2,5-furancarboxylic acid using catalyst
EP3179280A4 (en) Translucent structure, method for producing same, and product
WO2015168019A3 (en) Anti-ptk7 antibody-drug conjugates
EP3204488A4 (en) Engineered renal tissues, arrays thereof, and methods of making the same
EP3055318A4 (en) Dihydroxyalkyl substituted polygalactomannan, and methods for producing and using the same
EP3119424A4 (en) Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
EP3207789A4 (en) Grafted plant body and method for producing same
EP3315578A4 (en) Water repellent composition, method for producing water repellent composition, and article
EP3204342A4 (en) Compositions, panels and sheets comprising cellulose filaments and gypsum and methods for producing the same
EP3325608A4 (en) Methods and microorganisms for the production of 1,3-butanediol
EP3003297A4 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3277820A4 (en) Methods for producing modified red blood cell compositions, compositions and uses thereof
EP3163640A4 (en) Method for producing nanomaterial-dopant composition composite, nanomaterial-dopant composition composite, and dopant composition
EP3200817A4 (en) Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid
EP3156514A4 (en) Method for producing laminate, and laminate
EP3213775A4 (en) Deodorizer, deodorizing processed product produced using same, method for producing deodorizer, and method for producing deodorizing processed product
EP3202934A4 (en) Two-phase alloy, product obtained using said two-phase alloy, and process for producing said product
EP3401991A4 (en) System and method for producing 3.5-valent highly pure vanadium electrolyte

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14802997

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2014802997

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014802997

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2925332

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014341866

Country of ref document: AU

Date of ref document: 20141104

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016527404

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016009178

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112016009178

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160425